Under conditions of BTKi treatment, the blockade of BTK results in the modulation of the NF-κB signal transduction cascade, potentially leading to the induction of immunosuppression, deterioration of vascular function, and exacerbation of hypertension and enhancement of cardiovascular risk (Ahn and Brown, 2021). The gene discussed is NFKB1; the disease is hypertensive disorder.